相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
A. del Giglio et al.
BMC CANCER (2008)
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer:: A randomized phase 2 trial
G. Romieu et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim
Lodovico Balducci et al.
ONCOLOGIST (2007)
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
Michelle Shayne et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study
JN Timmer-Bonte et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
G Bonadonna et al.
BRITISH MEDICAL JOURNAL (2005)
The design and development of pegfilgrastim (PEG-rmetHuG-CSF, neulasta((R)))
G Molineux
CURRENT PHARMACEUTICAL DESIGN (2004)
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma
A Grigg et al.
LEUKEMIA & LYMPHOMA (2003)
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
JK Doorduijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment:: results of a Nordic Lymphoma Group randomized trial
E Ösby et al.
BLOOD (2003)
Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients
G Molineux
ANTI-CANCER DRUGS (2003)
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
MD Green et al.
ANNALS OF ONCOLOGY (2003)
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer
FA Holmes et al.
ANNALS OF ONCOLOGY (2002)
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer
FA Holmes et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cost effectiveness of treatment options in advanced breast cancer in the UK
RE Brown et al.
PHARMACOECONOMICS (2001)
分享论文
